Santen eyes uveitis market with top-line sirolimus data
This article was originally published in Scrip
Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.
Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.